Cargando…

Sildenafil does not enhance but rather attenuates vasorelaxant effects of antidiabetic agents

Type 2 diabetic men commonly experience erectile dysfunction for which phosphodiesterase-5 (PDE5) inhibitors like sildenafil (Viagra) are often recommended. By preventing degradation of cyclic guanosine monophosphate (cGMP) in vascular smooth muscle, these inhibitors also enhance arterial vasorelaxa...

Descripción completa

Detalles Bibliográficos
Autores principales: Peuler, Jacob D., Phelps, Laura E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japan Society of Smooth Muscle Research 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5137313/
https://www.ncbi.nlm.nih.gov/pubmed/26004378
http://dx.doi.org/10.1540/jsmr.51.22
_version_ 1782471893771616256
author Peuler, Jacob D.
Phelps, Laura E.
author_facet Peuler, Jacob D.
Phelps, Laura E.
author_sort Peuler, Jacob D.
collection PubMed
description Type 2 diabetic men commonly experience erectile dysfunction for which phosphodiesterase-5 (PDE5) inhibitors like sildenafil (Viagra) are often recommended. By preventing degradation of cyclic guanosine monophosphate (cGMP) in vascular smooth muscle, these inhibitors also enhance arterial vasorelaxant effects of nitric oxide donors (which stimulate cGMP synthesis). In the present work, we confirmed this enhancing effect after co-administration of sildenafil with nitroprusside to freshly-isolated rat tail arterial tissues. However, in the same tissues we also observed that sildenafil does not enhance but rather attenuates vasorelaxant effects of three commonly-used antidiabetic drugs, i.e. the biguanide metformin and the thiazolidinediones pioglitazone and rosiglitazone. Indeed, sildenafil completely blocked vasorelaxant effects of low concentrations of these drugs. In addition, we found that this same novel anti-vasorelaxant interaction of sildenafil with these agents was abolished by either 1) omitting extracellular glucose or 2) inhibiting specific smooth muscle glycolytic pathways; pathways known to preferentially utilize extracellular glucose to fuel certain adenosine triphosphate (ATP)-dependent ion transporters: e.g. ATP-sensitive K channels, sarcoplasmic reticulum Ca-ATPase, plasma membrane Ca-ATPase and Na/K-ATPase. Accordingly, we suspect that altered activity of one or more of these ion transporters mediates the observed attenuating (anti-vasorelaxant) interaction of sildenafil with the antidiabetic drugs. The present results are relevant because hypertension is so common and difficult to control in Type 2 diabetes. The present data suggest that sildenafil might interfere with the known antihypertensive potential of metformin and the thiazolidinediones. However, they do not suggest that it will interact with them to cause life-threatening episodes of severe hypotension, as can occur when it is co-administered with nitrates.
format Online
Article
Text
id pubmed-5137313
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Japan Society of Smooth Muscle Research
record_format MEDLINE/PubMed
spelling pubmed-51373132017-02-14 Sildenafil does not enhance but rather attenuates vasorelaxant effects of antidiabetic agents Peuler, Jacob D. Phelps, Laura E. J Smooth Muscle Res Original Type 2 diabetic men commonly experience erectile dysfunction for which phosphodiesterase-5 (PDE5) inhibitors like sildenafil (Viagra) are often recommended. By preventing degradation of cyclic guanosine monophosphate (cGMP) in vascular smooth muscle, these inhibitors also enhance arterial vasorelaxant effects of nitric oxide donors (which stimulate cGMP synthesis). In the present work, we confirmed this enhancing effect after co-administration of sildenafil with nitroprusside to freshly-isolated rat tail arterial tissues. However, in the same tissues we also observed that sildenafil does not enhance but rather attenuates vasorelaxant effects of three commonly-used antidiabetic drugs, i.e. the biguanide metformin and the thiazolidinediones pioglitazone and rosiglitazone. Indeed, sildenafil completely blocked vasorelaxant effects of low concentrations of these drugs. In addition, we found that this same novel anti-vasorelaxant interaction of sildenafil with these agents was abolished by either 1) omitting extracellular glucose or 2) inhibiting specific smooth muscle glycolytic pathways; pathways known to preferentially utilize extracellular glucose to fuel certain adenosine triphosphate (ATP)-dependent ion transporters: e.g. ATP-sensitive K channels, sarcoplasmic reticulum Ca-ATPase, plasma membrane Ca-ATPase and Na/K-ATPase. Accordingly, we suspect that altered activity of one or more of these ion transporters mediates the observed attenuating (anti-vasorelaxant) interaction of sildenafil with the antidiabetic drugs. The present results are relevant because hypertension is so common and difficult to control in Type 2 diabetes. The present data suggest that sildenafil might interfere with the known antihypertensive potential of metformin and the thiazolidinediones. However, they do not suggest that it will interact with them to cause life-threatening episodes of severe hypotension, as can occur when it is co-administered with nitrates. Japan Society of Smooth Muscle Research 2015-05-22 2015 /pmc/articles/PMC5137313/ /pubmed/26004378 http://dx.doi.org/10.1540/jsmr.51.22 Text en ©2015 The Japan Society of Smooth Muscle Research http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License.
spellingShingle Original
Peuler, Jacob D.
Phelps, Laura E.
Sildenafil does not enhance but rather attenuates vasorelaxant effects of antidiabetic agents
title Sildenafil does not enhance but rather attenuates vasorelaxant effects of antidiabetic agents
title_full Sildenafil does not enhance but rather attenuates vasorelaxant effects of antidiabetic agents
title_fullStr Sildenafil does not enhance but rather attenuates vasorelaxant effects of antidiabetic agents
title_full_unstemmed Sildenafil does not enhance but rather attenuates vasorelaxant effects of antidiabetic agents
title_short Sildenafil does not enhance but rather attenuates vasorelaxant effects of antidiabetic agents
title_sort sildenafil does not enhance but rather attenuates vasorelaxant effects of antidiabetic agents
topic Original
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5137313/
https://www.ncbi.nlm.nih.gov/pubmed/26004378
http://dx.doi.org/10.1540/jsmr.51.22
work_keys_str_mv AT peulerjacobd sildenafildoesnotenhancebutratherattenuatesvasorelaxanteffectsofantidiabeticagents
AT phelpslaurae sildenafildoesnotenhancebutratherattenuatesvasorelaxanteffectsofantidiabeticagents